

[Medroxyprogesterone acetate](#)

Essential medicine status

Section:

[18. Medicines for endocrine disorders 18.4. Progestogens](#)

ATC codes: [G03DA02](#)

Indication

Excessive menstruation with irregular cycle ICD11 code: [GA22](#)

INN

Medroxyprogesterone

Medicine type

Chemical agent

List type

Core

Formulations

**Oral > Solid:** 5 mg

EML status history

First added in 1993 ([TRS 850](#))

Changed in 2005 ([TRS 933](#))

Changed in 2011 ([TRS 965](#))

Changed in 2021 ([TRS 1035](#))

Sex

Female

Age

Adolescents and adults

Therapeutic alternatives

[norethisterone](#) (ATC codes: [G03DC02](#))

Patent information

Patents have expired in most jurisdictions

Read more [about patents](#).

Wikipedia

[Medroxyprogesterone acetate](#)

DrugBank

[Medroxyprogesterone acetate](#)

Summary of evidence and Expert Committee recommendations

Following the review of square box listings on the EML and EMLc, the Expert Committee recommended norethisterone be specified as a therapeutic alternative under the square box listing for medroxyprogesterone acetate on the EML for this indication.